Changes in B-type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function

David M Safley1, Ahmad Awad, Roberta A Sullivan

  • 1Department of Medicine, Cardiology and Nephrology Sections, Universtiy of Missouri-Kansas City School of Medicine, Truman Medical Center, Kansas City, MO, USA.

Insights

B-type natriuretic peptide (BNP) levels in end-stage renal disease (ESRD) patients slightly decreased after hemodialysis (HD). This reduction was more significant in patients with normal or mildly impaired left ventricular ejection fraction (LVEF), suggesting BNP may indicate HD fluid removal adequacy.

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Background:

  • B-type natriuretic peptide (BNP) is a cardiac neurohormone elevated in conditions of volume overload, common in end-stage renal disease (ESRD).
  • Hemodialysis (HD) is a treatment for ESRD aimed at fluid and waste removal, but its impact on cardiac biomarkers like BNP requires further investigation.

Purpose of the Study:

  • To evaluate the relative reduction in B-type natriuretic peptide (BNP) following hemodialysis (HD) in patients with end-stage renal disease (ESRD).
  • To explore the relationship between BNP reduction and baseline left ventricular ejection fraction (LVEF) and assess correlations with HD efficacy markers.

Main Methods:

  • A prospective pilot study involving 34 ESRD patients undergoing HD.
  • Serum BNP levels were measured before and after HD. Fluid removed, urea reduction ratio (URR), Kt/V, and left ventricular ejection fraction (LVEF) were recorded.
  • The BNP reduction ratio (BNPRR) was calculated as (pre-BNP - post-BNP) / pre-BNP.

Main Results:

  • BNP levels showed a slight mean decrease after HD (556.3 to 538.6 pg/mL).
  • BNP decreased in 66.7% of patients with measurable pre- and post-HD values.
  • The BNPRR correlated negatively with fluid volume removed, Kt/V, URR, and change in body weight, and was more pronounced in patients with normal/mildly impaired LVEF.

Conclusions:

  • BNP levels are elevated in ESRD patients and decrease slightly with hemodialysis.
  • The BNP reduction ratio (BNPRR) shows potential as a marker for the adequacy of fluid removal during hemodialysis, particularly in relation to left ventricular function.
  • Further research is warranted to validate BNPRR as a clinical indicator for optimizing HD treatment.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...